Entrectinib (Rozlytrek) manufacturer and correct usage

Enrectinib (Rozlytrek, Chinese trade name Luo Shengquan) is an innovative targeted therapy drug developed by Roche Genentech. The drug is mainly used to treat ROS1-positive metastatic non-small cell lung cancer in adults. It is also indicated for the treatment of adult and pediatric patients 1 month and older with solid tumors that harbor neurotrophic tyrosine receptor kinase (NTRK) gene fusions, have no known acquired resistance mutations, are metastatic or where surgical resection would result in significant morbidity, and have progressed following treatment or for which there are no satisfactory alternative therapies.

Enrectinib is a powerful and selective inhibitor for patients with tumors with specific genetic mutations. It can precisely block the activity ofTRK (tropomyosin receptor kinase) and ROS1 (a coding receptor tyrosine kinase), thereby inhibiting the growth and spread of tumor cells. In particular, entrectinib has the ability to cross the blood-brain barrier, which makes it unique in the treatment of primary and metastatic brain diseases.

Regarding the correct use of entrectinib, patients must strictly follow the doctor's instructions. First of all, entrectinib should be administered orally, and the tablets should be swallowed as whole as possible, avoiding chewing or crushing, so as not to affect the efficacy and dosage control of the drug. For patients with dysphagia, please use it under the guidance of a doctor.

The recommended dose for adult patients is generally 600 mg once daily until disease progression or unacceptable toxicity. The dosage for pediatric patients is adjusted based on body surface area and used under the guidance of physicians experienced in anti-cancer treatment. During the medication, patients should regularly monitor their physical condition and consult their doctor in time if they have any discomfort or questions.

In addition, entrectinib may interact with certain drugs, so patients should inform their doctors about all the drugs they are taking before taking the drug, including prescription drugs, over-the-counter drugs, health products, and Chinese herbal medicines. Particularly when used concomitantly with CYP3A inhibitors or inducers, the dose of entrectinib may need to be adjusted or concurrent use may need to be avoided. Additionally, grapefruit may interact with entrectinib and cause unwanted side effects, so avoid using grapefruit products.

In short, entrectinib (Rozlytrek), as an innovative drug carefully developed by Roche Genentech, brings new treatment hope to patients with tumors with specific genetic mutations. However, correct use is critical to ensure drug efficacy and patient safety. Therefore, patients must follow medical instructions when using entrectinib and maintain close communication with their doctors during treatment. Currently, this drug is available in both the original version and the affordable Lao version of the generic version. Patients should choose according to their needs, but be sure to choose formal channels.